Martha Metcalf, head of US credit strategies, said: “High yield has the potential to deliver good returns in 2021 from present valuation levels and the variation and dispersion in valuations means there are opportunities to generate returns through security selection. If the development of vaccines enables a normalisation in growth and company revenues, this is a potential kicker, but it will be very important to remain selective and focused on company analysis. In the meantime, many issuers have bolstered their liquidity and are positioned to navigate this challenging environment.”